Regent Pacific Group Limited
Regent Pacific Group Limited
Your view on RPGLF
Overview
What the company does, where it operates, and who runs it.
About Regent Pacific Group Limited
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Jamie Alexander Gibson
- Headquarters
- Henley Building, Central, HK
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Jamie Alexander Gibson
- Headquarters
- Henley Building, Central, HK
Regent Pacific Group Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in Europe and Taiwan. The company operates in two segments, Biopharma and Corporate Investment.
It engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels.
The company also invests in listed and unlisted corporate entities. In addition, it provides management services.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Regent Pacific Group Limited, and the rating behind it. RPGLF last traded at $0.13; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Regent Pacific Group Limited. Starting points for Regent Pacific Group Limited: EPS -$0.0067, beta 1.35 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Regent Pacific Group Limited. Regent Pacific Group Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Regent Pacific Group Limited. Trailing twelve-month EPS for Regent Pacific Group Limited stands at -$0.0067. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Regent Pacific Group Limited. Regent Pacific Group Limited has reported as a listed company since 1997. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Regent Pacific Group Limited valued side by side against its closest peers. Regent Pacific Group Limited is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Regent Pacific Group Limited, and how their positions are changing. At a $36.5M market value, institutional positions materially move Regent Pacific Group Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Regent Pacific Group Limited executives and directors. Shares of Regent Pacific Group Limited have traded between $0.0007 and $0.43 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Regent Pacific Group Limited. Regent Pacific Group Limited is a $36.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Regent Pacific Group Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Regent Pacific Group Limited. Coverage tracks Regent Pacific Group Limited within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.